个体化代谢手术评分:基于糖尿病严重程度选择术式
该研究基于659例接受RYGB或SG的T2DM患者(随访至少5年)构建IMS评分,并在241例西班牙患者中外部验证。IMS评分将T2DM分为3个严重阶段,指导个体化术式选择:轻度阶段两种术式均有效,重度阶段均疗效有限,中间阶段RYGB显著优于SG。
要点
- IMS评分基于糖尿病病程、降糖药数量、胰岛素使用和HbA1C<7%四个预测因子构建。
- IMS评分将T2DM分为轻、中、重3个严重阶段,指导术式选择。
- 中间严重阶段RYGB的糖尿病缓解率显著优于SG,推荐优先选择RYGB。
核心结论
- IMS评分可基于T2DM严重程度个体化选择RYGB或SG,并已外部验证。
研究设计与样本
- 美国单中心659例接受RYGB或SG的T2DM患者(2005-2011年,随访至少5年)构建模型,西班牙241例患者外部验证。
主要发现
- 中位随访7年(范围5-12年),RYGB术后糖尿病缓解率49%,SG为28%(P<0.001)。
- 长期缓解的四个独立预测因子:术前T2DM病程(P<0.0001)、术前降糖药数量(P<0.0001)、胰岛素使用(P=0.002)、血糖控制HbA1C<7%(P=0.002)。
- 轻度T2DM(IMS评分≤25)两种术式均显著改善T2DM;重度T2DM(IMS评分>95)两种术式缓解率均低;中间阶段RYGB显著优于SG。
关键数值与推荐
- IMS评分≤25为轻度T2DM,两种术式均有效。
- IMS评分>95为重度T2DM,两种术式缓解率均低。
- 中间阶段推荐RYGB,因其神经激素效应更显著。
临床怎么用
- 术前可使用IMS评分评估T2DM严重程度,据此选择RYGB或SG。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To construct and validate a scoring system for evidence-based selection of bariatric and metabolic surgery procedures according to severity of type 2 diabetes (T2DM). BACKGROUND: Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) account for >95% of bariatric procedures in United States in patients with T2DM. To date, there is no validated model to guide procedure selection based on long-term glucose control in patients with T2DM. METHODS: A total of 659 patients with T2DM who underwent RYGB and SG at an academic center in the United States and had a minimum 5-year follow-up (2005-2011) were analyzed to generate the model. The validation dataset consisted of 241 patients from an academic center in Spain where similar criteria were applied. RESULTS: At median postoperative follow-up of 7 years (range 5-12), diabetes remission (HbA1C <6.5% off medications) was observed in 49% after RYGB and 28% after SG (P < 0.001). Four independent predictors of long-term remission including preoperative duration of T2DM (P < 0.0001), preoperative number of diabetes medications (P < 0.0001), insulin use (P = 0.002), and glycemic control (HbA1C < 7%) (P = 0.002) were used to develop the Individualized Metabolic Surgery (IMS) score using a nomogram. Patients were then categorized into 3 stages of diabetes severity. In mild T2DM (IMS score ≤25), both procedures significantly improved T2DM. In severe T2DM (IMS score >95), when clinical features suggest limited functional β-cell reserve, both procedures had similarly low efficacy for diabetes remission. There was an intermediate group, however, in which RYGB was significantly more effective than SG, likely related to its more pronounced neurohormonal effects. Findings were externally validated and procedure recommendations for each severity stage were provided. CONCLUSIONS: This is the largest reported cohort (n = 900) with long-term postoperative glycemic follow-up, which, for the first time, categorizes T2DM into 3 validated severity stages for evidence-based procedure selection.
引用
- Aminian A, Brethauer SA, Andalib A, et al. Individualized Metabolic Surgery Score: Procedure Selection Based on Diabetes Severity. Ann Surg. 2017. PMID: 28742680. doi:10.1097/SLA.0000000000002407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。